Monopar Therapeutics Inc (MNPR) AI Stock Analysis

• Market Cap: $246.11M
• Dividend Yield: N/A
• Average Volume (3M): 36.31K
• Price to Earnings (P/E): ―
• Beta (1Y): 1.72
• Revenue Growth: N/A
• EPS Growth: -35.23%
• Country: US
• Employees: 9
• Sector: Healthcare
• Sector Strength: 72
• Industry: Biotechnology
• EPS (TTM): -1.98
• Shares Outstanding: 6,102,528
• 10 Day Avg. Volume: 31,085
• 30 Day Avg. Volume: 36,313
• PEG Ratio: N/A
• Price to Book (P/B): N/A
• Price to Sales (P/S): N/A
• Price to Cash Flow (P/CF): -49.20
• P/FCF Ratio: 0.00
• Enterprise Value/Market Cap: N/A
• Enterprise Value/Revenue: N/A
• Enterprise Value/Gross Profit: N/A
• Enterprise Value/Ebitda: N/A
• 1Y Price Target: $52.00
• Price Target Upside: 42.82% Upside
• Rating Consensus: Strong Buy
• Number of Analyst Covering: 3

Monopar’s overall stock score is primarily affected by its financial performance challenges, such as negative cash flows and lack of revenue. However, the strong cash position and debt-free status provide some stability. The technical indicators show neutral market sentiment, while the new CFO appointment brings a positive strategic outlook. The valuation reflects typical biotech hurdles with a negative P/E ratio.

Positive Factors

Market Potential

The high need for a new treatment modality in Wilson disease, due to inadequate control of symptoms by current options, suggests a strong market potential for ALXN1840.

Potential FDA Approval

The potential FDA approval of ALXN1840 is strong given the Phase 3 data and the unmet need in Wilson disease, particularly for patients with neurologic symptoms.

Strategic Licensing

The licensing agreement with AstraZeneca for ALXN-1840 is seen as a transformative event for Monopar Therapeutics Inc.

Negative Factors

Development Termination

Two Phase 2 mechanism of action studies failed to clearly demonstrate how ALXN-1840 clears copper from the body, leading AstraZeneca to terminate the development program.

Regulatory Challenges

Providing proof of fecal excretion of copper might require an additional study, posing a potential regulatory hurdle for ALXN1840's approval.

Monopar Therapeutics Inc Business Overview & Revenue Model

Company Description

Monopar Therapeutics Inc. (MNPR) is a clinical-stage biopharmaceutical company focused on developing innovative therapies to improve clinical outcomes for cancer patients. The company operates within the biotechnology and pharmaceuticals sectors, concentrating its efforts on advancing a pipeline of proprietary oncology drug candidates. Its core product candidates include therapies targeting severe side effects of chemotherapy and novel approaches to treat various types of cancer.

How the Company Makes Money

Monopar Therapeutics Inc. primarily makes money through the development and potential commercialization of its drug candidates. The company is in a clinical-stage, meaning its revenue model is largely oriented towards the successful advancement of its drug pipeline through clinical trials. Revenue streams may include potential milestone payments and royalties from partnerships or licensing agreements with larger pharmaceutical companies. Additionally, Monopar may receive government grants or funding from non-profit organizations to support its research and development efforts. The company's financial success is heavily reliant on the clinical and regulatory success of its product candidates, as well as its ability to establish strategic collaborations.

Monopar Therapeutics Inc Financial Statement Overview

Summary

Monopar Therapeutics Inc. is in a pre-revenue phase typical for biotech firms focused on R&D, with consistent operational losses and reliance on equity financing. While the absence of debt offers some flexibility, the ongoing net losses and decline in equity highlight financial risks.

Income Statement

Monopar Therapeutics Inc. has consistently reported zero revenue over the years, reflecting its pre-revenue status typical for biotechnology companies in the research phase. The company exhibits negative EBIT and net income margins, indicating ongoing operational losses without revenue streams to offset costs. This pattern underscores the high-risk nature of biotech investments dependent on future product success.

Balance Sheet

The balance sheet shows a strong equity position with no debt, which is favorable for financial stability. However, the declining stockholders' equity over time reflects continued net losses, reducing overall financial strength. The equity ratio remains high, indicating reliance on equity financing, which is common in this industry but could be a risk if equity continues to decline.

Cash Flow

The cash flow statement reveals negative operating and free cash flows, consistent with the company's developmental stage. However, cash reserves are actively managed through financing activities, evident from periodic injections of cash. This reliance on external financing highlights a potential risk if future funding becomes constrained.

Breakdown
TTM	Dec 2023	Dec 2022	Dec 2021	Dec 2020	Dec 2019
Income Statement		Total Revenue
0.00	0.00	0.00	0.00	0.00	0.00
	Gross Profit
0.00	0.00	0.00	0.00	0.00	0.00
	EBIT
-7.00M	-8.83M	-10.54M	-9.13M	-6.51M	-4.32M
	EBITDA
-1.57B	429.04K	0.00	0.00	0.00	0.00
	Net Income Common Stockholders
-1.31B	-8.40M	-10.49M	-9.08M	-6.22M	-4.13M
Balance Sheet		Cash, Cash Equivalents and Short-Term Investments
2.01M	7.27M	13.12M	20.30M	16.74M	13.21M
	Total Assets
0.00	7.35M	13.23M	20.52M	16.87M	13.35M
	Total Debt
0.00	0.00	8.41K	0.00	0.00	0.00
	Net Debt
2.01M	-7.27M	-8.18M	-20.30M	-16.74M	-13.21M
	Total Liabilities
0.00	1.76M	3.14M	1.58M	1.18M	724.16K
	Stockholders Equity
2.75M	5.59M	10.09M	18.94M	15.69M	12.63M
Cash Flow		Free Cash Flow
-5.95M	-7.86M	-7.23M	-7.32M	-4.66M	-3.02M
	Operating Cash Flow
-4.88M	-7.86M	-7.23M	-7.32M	-4.66M	-3.02M
	Investing Cash Flow
2.97M	4.93M	-4.92M	0.00	0.00	0.00
	Financing Cash Flow
3.49M	2.03M	32.87K	10.88M	8.18M	9.35M

Monopar Therapeutics Inc Technical Analysis

• Technical Analysis Sentiment: Neutral
• Last Price: 36.41
• 50DMA: Negative
• 100DMA: Positive
• 200DMA: Positive
• MACD: Negative
• RSI: Neutral
• STOCH: Neutral

Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For MNPR, the sentiment is Neutral. The current price of 36.41 is above the 20-day moving average (MA) of 34.65, below the 50-day MA of 38.20, and above the 200-day MA of 17.49, indicating a neutral trend. The MACD of 0.98 indicates Negative momentum. The RSI at 49.79 is Neutral, neither overbought nor oversold. The STOCH value of 49.12 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Neutral sentiment for MNPR.

Monopar Therapeutics Inc Peers Comparison

Name	Overall Rating	Market Cap	P/E Ratio	ROE	Dividend Yield	Revenue Growth	EPS Growth
CMPX	60 Neutral	$275.18M	―	-36.07%	―	―	-7.93%
CDTX	51 Neutral	$245.25M	―	-222.36%	―	-86.28%	-476.70%
Sector *	48 Neutral	$6.84B	1.02	-53.11%	2.50%	16.84%	0.92%
MNPR	48 Neutral	$246.11M	―	-51.42%	―	―	-35.23%
ITOS	48 Neutral	$241.39M	―	-23.06%	―	177.89%	-10.95%
XOMA	39 Underperform	$243.53M	―	-16.20%	―	498.72%	49.92%
ANNX	34 Underperform	$246.85M	―	-50.84%	―	―	43.21%

Monopar Therapeutics Inc Corporate Events

Monopar Therapeutics Appoints Quan Vu as New CFO

Monopar Therapeutics Inc. announced the termination of Karthik Radhakrishnan’s employment as Chief Financial Officer, principal financial officer, and principal accounting officer on February 28, 2025. The company’s Board of Directors appointed Quan Vu as the new CFO, effective March 3, 2025. Vu brings extensive experience in corporate and financial strategy, having previously served in various leadership roles in the biopharmaceutical and investment banking sectors. This leadership change is expected to impact Monopar’s financial strategy and operations positively.

Monopar Therapeutics Appoints Lavina Talukdar to Board

Monopar Therapeutics Inc. announced the resignation of Michael J. Brown from its Board of Directors effective February 19, 2025, and the appointment of Lavina Talukdar to the Board on February 21, 2025. Talukdar, who is currently the Senior Vice President, Head of Investor Relations at Moderna Inc., brings over 20 years of experience in investor relations and healthcare investments. Her appointment is expected to enhance Monopar’s strategic direction and governance, as she will also serve on several key committees within the company.